Purple Biotech says new U.S. patent allowance strengthens CAPTN-3 platform protection
Purple Biotech (PPBT) announced a U.S. patent allowance that strengthens protection for its CAPTN-3 modular platform for next-generation multispecific antibodies.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
PPBT - New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies - Click Fo
PPBT - New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies